NEW YORK (GenomeWeb) – Taking stock of Myriad Genetics pipeline and recent stock performance, Cowen and Co. analyst Doug Schenkel today upgraded the company’s stock to an Outperform rating from a previous Market Perform rating.

"In our base case, we see a path to low-single digit to mid-single digit growth supporting multiple expansion and 15 percent to 20 percent upside from current levels without broader GeneSight reimbursement," Schenkel wrote in a note to investors. "The risk/reward is attractive."